台灣皮膚科醫學會 蕁麻疹治療指引 2014.06
Taiwanese Dermatological Association Consensus for the definition, classification, diagnosis and management of urticaria
http://www.derma.org.tw/index.php?sort_no=1383033749
藥物治療:
第一線: 第二代抗組織胺 ex. Denosin (Desloratadine)
第二線: 第二代抗組織胺 加倍使用 Denosin 最高x4, or + 第一代抗組織胺
第三線: 增加Leukotriene antagonist ....
台大皮膚科醫師的使用經驗 levocetirizine (Xyzal),desloratadine(Denosin) 用於Urtucaria 效果遠遠優於 fexofenadine (Allegra).
唯 levocetirizine 劑量加倍使用時,患者昏睡會很嚴重.
若有Urticaria問題,七月份台大醫院皮膚部主治醫師朱家瑜將有"蕁麻疹 特別門診".
2014年6月9日 星期一
2014年6月4日 星期三
"健保不給付 罕病童相繼喪命" 是這樣嘛?
一早,看到FB上的訊息,
好奇的點進去看看內容.
沒想到竟然是由醫藥相關的社群轉貼這樣的新聞.
真的是....
健保不給付 罕病童相繼喪命
當你看到這樣的新聞,千萬要看清楚,不要被牽著鼻子走.
站在家屬角度: 為什麼罕病藥物健保不能給付?
站在國健局角度: 去年九月已經將此疾病列入罕見疾病.得核發重大傷並證明,免繳部份負擔.
站在健保署角度: 該Soliris尚未取得「非典型性溶血尿毒症」適應症,因此無法健保給付.
站在食藥署角度: 藥廠已申請該適應症,先前已討論過,近期會公佈適應症.
不同位置,當然說法會不同. 誰是誰非.絕非新聞敘述這麼容易辦別.
罕病用藥,固然單價會比較高.藥廠一定是希望健保給付才能拉高營業額.
而衛生主管機關,一定是依法行政,沒有適應症,怎麼給付啊?
(每兩個月開一次 全民健康保險藥事小組會議)
光看標題,或許你會究責通通都是健保的錯.
但實際上呢......
-----------------------------
補充一下好朋友的回應:
Liya : 藥廠不見得都希望要健保給付,因為特殊藥品有不可取代性時,自費市場更驚人。只是並不是人人都可以負擔,所以才會仰賴健保。
Brian: 不同藥品,不同病患群,操作方式一定不同.haha....
藥商也不想被健保署掐住,自費市場才是最愛...
好奇的點進去看看內容.
沒想到竟然是由醫藥相關的社群轉貼這樣的新聞.
真的是....
健保不給付 罕病童相繼喪命
當你看到這樣的新聞,千萬要看清楚,不要被牽著鼻子走.
站在家屬角度: 為什麼罕病藥物健保不能給付?
站在國健局角度: 去年九月已經將此疾病列入罕見疾病.得核發重大傷並證明,免繳部份負擔.
站在健保署角度: 該Soliris尚未取得「非典型性溶血尿毒症」適應症,因此無法健保給付.
站在食藥署角度: 藥廠已申請該適應症,先前已討論過,近期會公佈適應症.
不同位置,當然說法會不同. 誰是誰非.絕非新聞敘述這麼容易辦別.
罕病用藥,固然單價會比較高.藥廠一定是希望健保給付才能拉高營業額.
而衛生主管機關,一定是依法行政,沒有適應症,怎麼給付啊?
(每兩個月開一次 全民健康保險藥事小組會議)
光看標題,或許你會究責通通都是健保的錯.
但實際上呢......
-----------------------------
補充一下好朋友的回應:
Liya : 藥廠不見得都希望要健保給付,因為特殊藥品有不可取代性時,自費市場更驚人。只是並不是人人都可以負擔,所以才會仰賴健保。
Brian: 不同藥品,不同病患群,操作方式一定不同.haha....
藥商也不想被健保署掐住,自費市場才是最愛...
2014年6月3日 星期二
Easy Wallet悠 遊卡app
EasyWallet app
現在才知道,
原來我一個月搭捷運的費用約1500.
真是輔助的好工具!
不然之前都只是 嗶.. 嗶..
又都自動加值,
發票存在悠遊卡上,
根本不知道到底花了多少.....
防蟎大作戰
除濕機
醫師特別交代 濕度要維持50%
避免塵蟎滋生.
空氣清淨機
降低空氣中粉塵,
避免引發氣喘.
最新購入的Panasonic F-Y181BW 一級能效
吸塵器
傳聞中的除蟎吸塵器
單純吸枕頭、棉被、床墊
2014年6月2日 星期一
2014年5月21日 星期三
2014年5月20日 星期二
肝腎功能不好 用藥調整
許多藥物,碰到肝腎功能不好的病人,劑量可能需要調整.
仿單上可能會註明:
2.5 Adults with Hepatic or Renal Impairment In adult patients with liver or renal impairment, a starting dose of one 5-mg tablet every other day is recommended based on pharmacokinetic data.
仔細找找原廠的仿單,後面有提到該要針對肝腎功能不全的患者,所作的臨床試驗結果.
總試驗人數內.什麼樣的肝腎功能不全佔多少人,如何影響藥物的代謝.
Renally Impaired: Desloratadine pharmacokinetics following a single dose of 7.5 mg were characterized in patients with mild(n=7; creatinine clearance 51–69 mL/min/1.73 m2), moderate (n=6; creatinine clearance 34–43 mL/min/1.73 m2), and severe (n=6;creatinine clearance 5–29 mL/min/1.73 m2) renal impairment or hemodialysis dependent (n=6) patients. In patients with mild and moderate renal impairment, median Cmax and AUC values increased by approximately 1.2- and 1.9-fold, respectively, relativeto subjects with normal renal function. In patients with severe renal impairment or who were hemodialysis dependent, Cmax and AUC values increased by approximately 1.7- and 2.5-fold, respectively. Minimal changes in 3-hydroxydesloratadine concentrations were observed. Desloratadine and 3-hydroxydesloratadine were poorly removed by emodialysis. Plasma protein binding of desloratadine and 3-hydroxydesloratadine was unaltered by renal impairment. Dosage adjustment for patients with renal impairment is recommended.
Hepatically Impaired: Desloratadine pharmacokinetics were characterized following a single oral dose in patients with mild (n=4), moderate (n=4), and severe (n=4) hepatic impairment as defined by the Child-Pugh classification of hepatic function and 8 subjects with normal hepatic function. Patients with hepatic impairment, regardless of severity, had approximately a 2.4-fold increase in AUC as compared with normal subjects. The apparent oral clearance of desloratadine in patients with mild, moderate, and severe
hepatic impairment was 37%, 36%, and 28% of that in normal subjects, respectively. An increase in the mean elimination half-life of desloratadine in patients with hepatic impairment was observed. For 3-hydroxydesloratadine, the mean Cmax and AUC values for patients with hepatic impairment were no statistically significantly different from subjects with normal hepatic function. Dosage adjustment for patients with hepatic impairment is recommended [see Dosage and Administration (2.5)].
不過坦白說,也不是所有的都寫得很清楚,大部分就只提到肝腎功能不全的患者,劑量要做調整.
但是肝腎功能不全的臨床指標及判別,還是由醫師做判斷.當然各院的標準可能不一.
我雖然想給正確的臨床判別數字,但真的沒有啊!!!
腎功能不全病人的藥物劑量調整-三總藥訊
仿單上可能會註明:
2.5 Adults with Hepatic or Renal Impairment In adult patients with liver or renal impairment, a starting dose of one 5-mg tablet every other day is recommended based on pharmacokinetic data.
仔細找找原廠的仿單,後面有提到該要針對肝腎功能不全的患者,所作的臨床試驗結果.
總試驗人數內.什麼樣的肝腎功能不全佔多少人,如何影響藥物的代謝.
Renally Impaired: Desloratadine pharmacokinetics following a single dose of 7.5 mg were characterized in patients with mild(n=7; creatinine clearance 51–69 mL/min/1.73 m2), moderate (n=6; creatinine clearance 34–43 mL/min/1.73 m2), and severe (n=6;creatinine clearance 5–29 mL/min/1.73 m2) renal impairment or hemodialysis dependent (n=6) patients. In patients with mild and moderate renal impairment, median Cmax and AUC values increased by approximately 1.2- and 1.9-fold, respectively, relativeto subjects with normal renal function. In patients with severe renal impairment or who were hemodialysis dependent, Cmax and AUC values increased by approximately 1.7- and 2.5-fold, respectively. Minimal changes in 3-hydroxydesloratadine concentrations were observed. Desloratadine and 3-hydroxydesloratadine were poorly removed by emodialysis. Plasma protein binding of desloratadine and 3-hydroxydesloratadine was unaltered by renal impairment. Dosage adjustment for patients with renal impairment is recommended.
Hepatically Impaired: Desloratadine pharmacokinetics were characterized following a single oral dose in patients with mild (n=4), moderate (n=4), and severe (n=4) hepatic impairment as defined by the Child-Pugh classification of hepatic function and 8 subjects with normal hepatic function. Patients with hepatic impairment, regardless of severity, had approximately a 2.4-fold increase in AUC as compared with normal subjects. The apparent oral clearance of desloratadine in patients with mild, moderate, and severe
hepatic impairment was 37%, 36%, and 28% of that in normal subjects, respectively. An increase in the mean elimination half-life of desloratadine in patients with hepatic impairment was observed. For 3-hydroxydesloratadine, the mean Cmax and AUC values for patients with hepatic impairment were no statistically significantly different from subjects with normal hepatic function. Dosage adjustment for patients with hepatic impairment is recommended [see Dosage and Administration (2.5)].
不過坦白說,也不是所有的都寫得很清楚,大部分就只提到肝腎功能不全的患者,劑量要做調整.
但是肝腎功能不全的臨床指標及判別,還是由醫師做判斷.當然各院的標準可能不一.
我雖然想給正確的臨床判別數字,但真的沒有啊!!!
腎功能不全病人的藥物劑量調整-三總藥訊
2014年5月2日 星期五
訂閱:
文章 (Atom)















